Incident pulmonary arterial hypertension associated with Bosutinib.

Macitentan chronic myeloid leukemia drug-induced pulmonary hypertension tyrosine kinase inhibitors

Journal

Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243

Informations de publication

Date de publication:
Historique:
received: 03 03 2020
accepted: 29 05 2020
entrez: 11 9 2020
pubmed: 12 9 2020
medline: 12 9 2020
Statut: epublish

Résumé

Pulmonary arterial hypertension is associated with tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia. Dasatinib is a known cause of drug-induced pulmonary arterial hypertension. There have been case reports linking Bosutinib with deterioration of pre-existing pulmonary arterial hypertension. Here, we present a case of a 37-year-old woman with chronic myeloid leukemia treated with Bosutinib who was diagnosed with pulmonary arterial hypertension. Prior to Bosutinib, she had received Dasatinib without documented cardiopulmonary toxicity. Withdrawal of Bosutinib led to partial reversal of pulmonary arterial hypertension, and with the addition of pulmonary arterial hypertension-targeted treatment, there was near normalization of hemodynamics.

Identifiants

pubmed: 32913629
doi: 10.1177/2045894020936913
pii: 10.1177_2045894020936913
pmc: PMC7443988
doi:

Types de publication

Case Reports

Langues

eng

Pagination

2045894020936913

Informations de copyright

© The Author(s) 2020.

Références

J Clin Oncol. 2018 Jan 20;36(3):231-237
pubmed: 29091516
J Clin Oncol. 2015 Dec 10;33(35):4210-8
pubmed: 26371140
Circulation. 2012 May 1;125(17):2128-37
pubmed: 22451584
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Eur Respir J. 2016 Feb;47(2):676-9
pubmed: 26743481
Eur Respir J. 2016 Nov;48(5):1514-1516
pubmed: 27660511
Eur Respir J. 2016 Nov;48(5):1517-1519
pubmed: 27799395
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971
Eur Respir J. 2019 May 9;53(5):
pubmed: 30846469
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751413
Pulm Circ. 2017 Oct-Dec;7(4):808-812
pubmed: 28914582
Eur Respir J. 2013 Jan;41(1):85-95
pubmed: 22523355
Leuk Lymphoma. 2018 Jul;59(7):1523-1538
pubmed: 28972424

Auteurs

Shaun Yo (S)

Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

John Thenganatt (J)

Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Jeffrey Lipton (J)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

John Granton (J)

Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Classifications MeSH